Concurrently, clinical data revealed that advanced HCC patients with lower LSD1 levels experienced a prolonged DoR to anti‐PD1 therapy compared to patients expressing higher levels of LSD1. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.